
	Medicaid		Medicare		Commercial		Other		Consolidated Total
Balance, January 1, 2026	$	10,375	$	4,401	$	5,683	$	85	$	20,544
Less: Reinsurance recoverable	16		—		60		—		76
Balance, January 1, 2026, net	10,359		4,401		5,623		85		20,468

Incurred related to:
Current year	66,889		29,496		22,827		1,108		120,320
Prior years	(1,101)		(268)		(478)		(13)		(1,860)
Total incurred	65,788		29,228		22,349		1,095		118,460
Paid related to:
Current year	56,197		25,236		18,504		1,100		101,037
Prior years	8,300		3,773		4,303		70		16,446
Total paid	64,497		29,009		22,807		1,170		117,483

Balance, September 30, 2026, net	11,650		4,620		5,165		10		21,445
Plus: Reinsurance recoverable	15		—		35		—		50
Balance, September 30, 2026	$	11,665	$	4,620	$	5,200	$	10	$	21,495


	Medicaid		Medicare		Commercial		Other		Consolidated Total
Balance, January 1, 2025	$	10,299	$	3,358	$	4,463	$	188	$	18,308
Less: Reinsurance recoverable	18		—		47		—		65
Balance, January 1, 2025, net	10,281		3,358		4,416		188		18,243

Incurred related to:
Current year	64,181		25,306		27,111		1,597		118,195
Prior years	(1,143)		(501)		(504)		(24)		(2,172)
Total incurred	63,038		24,805		26,607		1,573		116,023
Paid related to:
Current year	53,764		21,544		22,201		1,426		98,935
Prior years	8,229		2,461		3,250		161		14,101
Total paid	61,993		24,005		25,451		1,587		113,036
Plus: Premium deficiency reserve	—		190		—		—		190
Balance, September 30, 2025, net	11,326		4,348		5,572		174		21,420
Plus: Reinsurance recoverable	17		—		56		—		73
Balance, September 30, 2025	$	11,343	$	4,348	$	5,628	$	174	$	21,493

Reinsurance recoverables related to medical claims are included in premium and trade receivables. Changes in estimates of incurred claims for prior years are primarily attributable to reserving under moderately adverse conditions. Additionally, as a result of development within "Incurred related to: Prior years," the Company recorded $35 million and $86 million as a reduction to premium revenue in the nine months ended September 30, 2026 and 2025, respectively, for minimum medical loss ratio (MLR) and other return of premium programs.

Incurred but not reported (IBNR) plus expected development on reported claims as of September 30, 2026 was $12,184 million. Total IBNR plus expected development on reported claims represents estimates for claims incurred but not reported, development on reported claims and estimates for the costs necessary to process unpaid claims at the end of each period. The Company estimates its liability using actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. These actuarial methods consider factors such as historical data for payment patterns, cost trends, product mix, seasonality, utilization of healthcare services and other relevant factors.

The Company reviews actual and anticipated experience compared to the assumptions used to establish medical costs. The Company establishes premium deficiency reserves if actual and anticipated experience indicates that existing policy liabilities together with the present value of future gross premiums will not be sufficient to cover the present value of future benefits, settlement and maintenance costs. For purposes of determining premium deficiencies, contracts are grouped in a manner consistent with the method of acquiring, servicing and measuring the profitability of such contracts and expected investment income is excluded. In December 2024, the Company recorded a premium deficiency reserve of $92 million related to the 2025 Medicare Advantage contract year, which was increased to $270 million in the first quarter of 2025 and to $389 million in the second quarter of 2025 and decreased by $107 million to $282 million in the third quarter of 2025 based on the progression of earnings during the year (with higher earnings at the beginning of the year and lower at the end of the year, given cost sharing progression), including anticipated impacts of the Inflation Reduction Act to the Part D benefit within the Company's Medicare Advantage business. As of September 2026, the Company did not record a premium deficiency reserve related to the 2026 Medicare Advantage contract year.